Melanotan I (MT-1 / Afamelanotide)

Afamelanotide for Erythropoietic Protoporphyria

Langendonk JG et al. · The New England journal of medicine · 2015

Population: Adults with erythropoietic protoporphyria

The controlled trials of afamelanotide in erythropoietic protoporphyria, measuring pain-free time tolerated in sunlight.

Route reported

Subcutaneous implant

Duration

Multiple treatment periods across two trials

Context: Studied a controlled-release pharmaceutical implant in a rare photodermatosis. It does not describe cosmetic tanning use, and the material is not comparable.

Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ([Nle4-D-Phe7]-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies

Lengweiler S et al. · Skin pharmacology and physiology · 2015

The study reportedThe new ELISA is suitable to determine ADA against afamelanotide and α-MSH. Afamelanotide did not elicit ADA during long-term administration in patients with EPP.

Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris

Böhm M et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2014

The study reportedAfamelanotide appears to have anti-inflammatory effects in patients with mild-to-moderate acne vulgaris. Future trials are needed to confirm the anti-inflammatory action of this melanocortin analogue in patients with acne vulgaris.

Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease

Biolcati G et al. · Clinical and experimental dermatology · 2014

The study reportedAfamelanotide is effective for the treatment of skin lesions in HHD.

[Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers

Barnetson RS et al. · The Journal of investigative dermatology · 2006

The study reportedThis study has shown for the first time the potential ability of a synthetic hormone that augments melanin production to provide photoprotection to people who normally burn in direct sunlight.